Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 5/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16768023 | 0.88 | HRH3 (0.53) | PDK1HRH3CCR2KCNH2NPSR1 | |
| SCHEMBL16768128 | 0.85 | HRH3 (0.51) | PDK1HRH3CCR2KCNH2NPSR1 | |
| SCHEMBL16768019 | 0.85 | HRH3 (0.51) | PDK1HRH3CCR2KCNH2NPSR1 | |
| SCHEMBL16768026 | 0.84 | HRH3 (0.50) | PDK1HRH3CCR2KCNH2NPSR1 | |
| SCHEMBL16767981 | 0.83 | HRH3 (0.49) | PDK1HRH3CCR2KCNH2NPSR1 | |
| SCHEMBL26723897 | 0.82 | HRH3 (0.51) | PDK1HRH3CCR2KCNH2NPSR1 | |
| SCHEMBL26723898 | 0.80 | HRH3 (0.49) | PDK1HRH3CCR2KCNH2NPSR1 | |
| SCHEMBL17020104 | 0.80 | PDK1 (0.62) | PDK1HRH3ALDH1A1SYKNLRP3 | |
| SCHEMBL16369427 | 0.80 | HRH3 (0.47) | PDK1HRH3CCR2KCNH2NPSR1 | |
| SCHEMBL20179866 | 0.79 | HRH3 (0.54) | PDK1HRH3CCR2KCNH2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353066-B2 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | PDK1 721/4885HRH3 653/4885CCR2 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.